Corient Private Wealth LLC Sells 179,789 Shares of Pfizer Inc. $PFE

Corient Private Wealth LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 8.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,054,574 shares of the biopharmaceutical company’s stock after selling 179,789 shares during the period. Corient Private Wealth LLC’s holdings in Pfizer were worth $49,803,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Caldwell Trust Co bought a new position in shares of Pfizer in the second quarter worth $1,275,000. Watts Gwilliam & Co. LLC boosted its stake in Pfizer by 176.9% during the second quarter. Watts Gwilliam & Co. LLC now owns 79,423 shares of the biopharmaceutical company’s stock valued at $1,918,000 after buying an additional 50,744 shares during the period. NWF Advisory Services Inc. grew its position in Pfizer by 3.2% during the second quarter. NWF Advisory Services Inc. now owns 37,656 shares of the biopharmaceutical company’s stock worth $913,000 after buying an additional 1,162 shares in the last quarter. Total Investment Management Inc. bought a new position in Pfizer in the 2nd quarter worth about $179,000. Finally, Orion Porfolio Solutions LLC raised its holdings in shares of Pfizer by 6.1% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 709,250 shares of the biopharmaceutical company’s stock valued at $17,192,000 after acquiring an additional 40,805 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Price Performance

PFE stock opened at $25.56 on Wednesday. The firm has a market cap of $145.34 billion, a P/E ratio of 14.86 and a beta of 0.46. The firm’s fifty day moving average is $25.11 and its 200 day moving average is $24.81. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The business had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PFE shares. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday, October 8th. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target for the company. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price objective on shares of Pfizer in a research report on Wednesday, November 5th. HSBC reaffirmed a “buy” rating and set a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Finally, UBS Group reissued a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.22.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.